After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Mylan has struggled for a while with a challenging generic drug market, in the U.S. especially, weighing on its growth. The proposed transaction will combine Mylan with Upjohn, the Pfizer segment ...

Mylan, the profiteering, tax-dodging drug company currently taking immense heat for jacking up the price of its Epipen by 500%, announced Thursday that it will help more patients cover their ...

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...

Mylan has a board-election battle on its hands. Some powerful institutional investors are steamed about Mylan Chairman Robert Coury’s $97 million compensation in 2016—and they’re calling on ...

Mylan Inc. CEO Heather Bresch testifies during a hearing before the House Oversight and Government...[+] Reform Committee September 21, 2016 on Capitol Hill in Washington, D.C. (Photo by Alex Wong ...

Mylan's report follows an earnings beat by Merck&Co on February 5, who reported EPS of $1.16 on revenue of $11.87B, compared to forecasts EPS of $1.15 on revenue of $11.98B.

Meanwhile, Mylan used smear tactics, producing a study that seemed to question the Food and Drug Administration’s decision to deem Auvi-Q “bioequivalent” to EpiPen, Sanofi alleges.

The worst appears to be over for Mylan NV and its EpiPen controversy. It took a $465 million settlement with the U.S. Justice Department and a grilling from Congress for its chief executive ...

Mylan declined to comment on this, but did point to an analyst report from Susquehanna Financial Group's Andrew Finkelstein. The report estimated that Mylan's net earnings per generic two-pack ...

Mylan also said it would offer a $25 discount on the co-pays for buyers with health insurance, and a savings card good for a discount of up to $300 on deductible or co-pay expenses for the branded ...

Mylan shares were up more than 12 percent, at $20.78. Follow Michael J. de la Merced and Katie Thomas on Twitter: @m_delamerced and @katie_thomas.